MUFG Americas’s Cascadian Therapeutics, Inc. CASC Stock Holding History

MUFG Americas’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-288	Closed	-$5K	–	1278
2015 Q3	$5K	Buy	288 +23	+9%	+$472	﹤0.01%	973
2015 Q2	$6K	Sell	265 -310	-54%	-$4.9K	﹤0.01%	956
2015 Q1	$6K	Buy	575 +115	+25%	+$1.13K	﹤0.01%	1008
2014 Q4	$5K	Buy	460 +177	+63%	+$1.92K	﹤0.01%	1097
2014 Q3	$3K	Buy	+283	New	+$4.32K	﹤0.01%	1187
2013 Q3	–	Sell	-4	Closed	–	–	1591
2013 Q2	$0	Buy	+4	New	+$51	﹤0.01%	1615

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

MUFG Americas's CASC Position: Q4 2015 in Review

MUFG Americas sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 288 shares — an estimated $5K sold.

MUFG Americas first reported a position in CASC in Q2 2013 and held it in 6 quarters. The position peaked at $6K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

MUFG Americas reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
MUFG Americas sold 288 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $5K.
MUFG Americas first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
MUFG Americas's Cascadian Therapeutics, Inc. position peaked at $6K in Q2 2015.
93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on MUFG Americas's 13F filing for Q4 2015, filed 10 Feb 2016.